Department of Brain and Cognitive Sciences, 775 Library Road, University of Rochester, Rochester, NY 14627, USA.
Curr Alzheimer Res. 2013 Sep;10(7):732-41. doi: 10.2174/15672050113109990148.
This paper investigates how commonly prescribed pharmacologic treatments for Alzheimer's disease (AD) affect Event-Related Potential (ERP) biomarkers as tools for predicting AD conversion in individuals with Mild Cognitive Impairment (MCI). We gathered baseline ERP data from two MCI groups (those taking AD medications and those not) and later determined which subjects developed AD (Convert->AD) and which subjects remained cognitively stable (Stable). We utilized a previously developed and validated multivariate system of ERP components to measure medication effects among these four subgroups. Discriminant analysis produced classification scores for each individual as a measure of similarity to each clinical group (Convert->AD, Stable), and we found a large significant main Group effect but no main AD Medications effect and no Group by Medications interaction. This suggested AD medications have negligible influence on this set of ERP components as weighted markers of disease progression. These results provide practical information to those using ERP measures as a biomarker to identify and track AD in individuals in a clinical or research setting.
本研究旨在探讨常用于治疗阿尔茨海默病（AD）的药物治疗如何影响事件相关电位（ERP）生物标志物，作为预测轻度认知障碍（MCI）个体 AD 转化的工具。我们收集了两个 MCI 组（服用 AD 药物的组和未服用 AD 药物的组）的基线 ERP 数据，然后确定哪些受试者发展为 AD（转化为 AD），哪些受试者保持认知稳定（稳定）。我们利用先前开发和验证的 ERP 成分多变量系统来衡量这四个亚组中药物的作用。判别分析为每个个体生成分类评分，作为与每个临床组（转化为 AD、稳定）相似性的衡量标准，我们发现了一个很大的显著的主要组效应，但没有主要的 AD 药物效应，也没有组与药物的相互作用。这表明 AD 药物对这组 ERP 成分作为疾病进展的加权标志物几乎没有影响。这些结果为那些将 ERP 测量作为生物标志物在临床或研究环境中识别和跟踪 AD 的人提供了实用信息。
